| Nov 12 |
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 11 |
Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
|
| Nov 9 |
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
|
| Nov 8 |
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
|
| Nov 8 |
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...
|
| Nov 8 |
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
Iovance falls 12% despite Q3 beats; reaffirms 2024 revenue guidance
|
| Nov 7 |
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 7 |
Iovance Biotherapeutics: Q3 Earnings Snapshot
|
| Nov 7 |
Iovance Biotherapeutics GAAP EPS of -$0.28 beats by $0.02, revenue of $58.6M beats by $4.78M
|
